The deubiquitylase USP9X controls ribosomal stalling.


Journal

The Journal of cell biology
ISSN: 1540-8140
Titre abrégé: J Cell Biol
Pays: United States
ID NLM: 0375356

Informations de publication

Date de publication:
01 03 2021
Historique:
received: 27 04 2020
accepted: 11 12 2020
entrez: 28 1 2021
pubmed: 29 1 2021
medline: 10 9 2021
Statut: ppublish

Résumé

When a ribosome stalls during translation, it runs the risk of collision with a trailing ribosome. Such an encounter leads to the formation of a stable di-ribosome complex, which needs to be resolved by a dedicated machinery. The initial stalling and the subsequent resolution of di-ribosomal complexes requires activity of Makorin and ZNF598 ubiquitin E3 ligases, respectively, through ubiquitylation of the eS10 and uS10 subunits of the ribosome. We have developed a specific small-molecule inhibitor of the deubiquitylase USP9X. Proteomics analysis, following inhibitor treatment of HCT116 cells, confirms previous reports linking USP9X with centrosome-associated protein stability but also reveals a loss of Makorin 2 and ZNF598. We show that USP9X interacts with both these ubiquitin E3 ligases, regulating their abundance through the control of protein stability. In the absence of USP9X or following chemical inhibition of its catalytic activity, levels of Makorins and ZNF598 are diminished, and the ribosomal quality control pathway is impaired.

Identifiants

pubmed: 33507233
pii: 211735
doi: 10.1083/jcb.202004211
pmc: PMC7849821
pii:
doi:

Substances chimiques

Antibodies 0
Carrier Proteins 0
MKRN2 protein, human 0
Ribonucleoproteins 0
USP9X protein, human 0
ZNF598 protein, human 0
Ubiquitin Thiolesterase EC 3.4.19.12

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Medical Research Council
ID : MR/N013840/1
Pays : United Kingdom

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2021 Clancy et al.

Références

Nat Chem Biol. 2018 Feb;14(2):118-125
pubmed: 29200206
Wiley Interdiscip Rev RNA. 2018 Jun 5;:e1486
pubmed: 29869837
Cell Rep. 2019 Aug 13;28(7):1679-1689.e4
pubmed: 31412239
Mol Cell. 2004 Mar 26;13(6):879-86
pubmed: 15053880
Sci Adv. 2015 Jul;1(6):
pubmed: 26322332
Mol Cell. 2018 Nov 1;72(3):469-481.e7
pubmed: 30293783
Nucleic Acids Res. 2020 Feb 20;48(3):1043-1055
pubmed: 31598688
J Proteome Res. 2017 Mar 3;16(3):1288-1299
pubmed: 28164708
Nat Commun. 2017 Mar 31;8:14866
pubmed: 28361952
Elife. 2019 Nov 21;8:
pubmed: 31749445
Cell Rep. 2019 Jul 23;28(4):1074-1089.e5
pubmed: 31340145
Biochem J. 2018 Apr 30;475(8):1507-1522
pubmed: 29626158
Nat Rev Mol Cell Biol. 2019 Jun;20(6):338-352
pubmed: 30733604
J Cell Sci. 2019 Jan 22;132(2):
pubmed: 30584065
Trends Cell Biol. 2015 Jul;25(7):417-26
pubmed: 25906909
Genome Biol. 2019 Oct 22;20(1):216
pubmed: 31640799
Nature. 2017 Oct 26;550(7677):481-486
pubmed: 29045389
Mol Cell. 2017 Feb 16;65(4):743-750.e4
pubmed: 28065601
Elife. 2020 Feb 03;9:
pubmed: 32011234
J Cell Sci. 2020 Feb 12;133(3):
pubmed: 31964704
Cell. 2012 Nov 21;151(5):1042-54
pubmed: 23178123
Cell. 2017 Jun 1;169(6):1051-1065.e18
pubmed: 28575669
Nat Commun. 2017 Jul 07;8:16056
pubmed: 28685749
Science. 2014 Jul 25;345(6195):455-9
pubmed: 25061210
Cell Chem Biol. 2017 Dec 21;24(12):1490-1500.e11
pubmed: 29056421
Nature. 2017 Oct 26;550(7677):534-538
pubmed: 29045385
Cancer Biol Ther. 2012 Nov;13(13):1319-24
pubmed: 22895071
Nat Commun. 2014 Aug 27;5:4763
pubmed: 25159004
Nature. 2010 Jan 7;463(7277):103-7
pubmed: 20023629
Annu Rev Cell Dev Biol. 2017 Oct 6;33:343-368
pubmed: 28715909
Traffic. 2008 Jul;9(7):1130-45
pubmed: 18410486
Chem Biol. 2002 Oct;9(10):1149-59
pubmed: 12401499
Nature. 2019 Apr;568(7753):511-516
pubmed: 30971826
Chem Biol. 2013 Dec 19;20(12):1447-55
pubmed: 24290882
Cell. 2010 Dec 10;143(6):1018-29
pubmed: 21145465
Blood. 2015 Jun 4;125(23):3588-97
pubmed: 25814533
Cell Rep. 2018 Apr 17;23(3):852-865
pubmed: 29669289
Chem Biol. 2011 Nov 23;18(11):1401-12
pubmed: 22118674
Theranostics. 2018 Mar 22;8(9):2348-2360
pubmed: 29721084
Curr Biol. 2016 Jan 25;26(2):173-183
pubmed: 26748853
J Biol Chem. 2017 Aug 4;292(31):12874-12884
pubmed: 28620049
Nat Protoc. 2016 Dec;11(12):2301-2319
pubmed: 27809316
Mol Cell. 2017 Feb 16;65(4):751-760.e4
pubmed: 28132843
Mol Biol Cell. 2012 Mar;23(6):1095-103
pubmed: 22298430
Cell Mol Life Sci. 2015 Jun;72(11):2075-89
pubmed: 25672900
Am J Hum Genet. 2016 Feb 4;98(2):373-81
pubmed: 26833328

Auteurs

Anne Clancy (A)

Department of Molecular Physiology and Cell Signaling, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.

Claire Heride (C)

Department of Molecular Physiology and Cell Signaling, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
Cancer Research UK Therapeutic Discovery Laboratories, London Bioscience Innovation Centre, London, UK.

Adán Pinto-Fernández (A)

Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Hannah Elcocks (H)

Department of Molecular Physiology and Cell Signaling, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.

Andreas Kallinos (A)

Department of Molecular Physiology and Cell Signaling, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.

Katherine J Kayser-Bricker (KJ)

FORMA Therapeutics, Watertown, MA.

Weiping Wang (W)

FORMA Therapeutics, Watertown, MA.

Victoria Smith (V)

Department of Molecular Physiology and Cell Signaling, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.

Simon Davis (S)

Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Shawn Fessler (S)

FORMA Therapeutics, Watertown, MA.

Crystal McKinnon (C)

FORMA Therapeutics, Watertown, MA.

Marie Katz (M)

FORMA Therapeutics, Watertown, MA.

Tim Hammonds (T)

Cancer Research UK Therapeutic Discovery Laboratories, London Bioscience Innovation Centre, London, UK.

Neil P Jones (NP)

Cancer Research UK Therapeutic Discovery Laboratories, London Bioscience Innovation Centre, London, UK.

Jonathan O'Connell (J)

FORMA Therapeutics, Watertown, MA.

Bruce Follows (B)

FORMA Therapeutics, Watertown, MA.

Steven Mischke (S)

FORMA Therapeutics, Watertown, MA.

Justin A Caravella (JA)

FORMA Therapeutics, Watertown, MA.

Stephanos Ioannidis (S)

FORMA Therapeutics, Watertown, MA.

Christopher Dinsmore (C)

FORMA Therapeutics, Watertown, MA.

Sunkyu Kim (S)

FORMA Therapeutics, Watertown, MA.

Axel Behrens (A)

Adult Stem Cell Laboratory, Francis Crick Institute, London, UK.

David Komander (D)

Ubiquitin Signalling Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Department of Medical Biology, University of Melbourne, Melbourne, Victoria, Australia.

Benedikt M Kessler (BM)

Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

Sylvie Urbé (S)

Department of Molecular Physiology and Cell Signaling, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.

Michael J Clague (MJ)

Department of Molecular Physiology and Cell Signaling, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH